Latest News-Deqi(Zhejiang)Pharmaceutical Technology Co. Ltd. Mediaroom_Page

Antengene to Present at the 41st Annual J.P. Morgan Healthcare Conference

SHANGHAI and HONG KONG, Jan. 3, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEH...

2023-01-03 14:10 1916

Antengene Enters into a Global Clinical Collaboration with MSD to Evaluate ATG-037 (CD73 Inhibitor) in Combination with KEYTRUDA® (pembrolizumab)

- ATG-037 is Antengene's oral small molecule CD73 inhibitor; KEYTRUDA® (pembrolizumab) is MSD's ant...

2022-12-27 08:30 3168

Antengene Announces NDA Submission for XPOVIO® in Macau, Malaysia and Thailand for Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-cell Lymphoma

SHANGHAI and HONG KONG, Dec. 23, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SE...

2022-12-23 08:30 3379

Antengene Announces HREC Approval in Australia for the Phase I Trial of ATG-022 (Claudin 18.2 ADC) in Patients with Advanced or Metastatic Solid Tumors

* Discovered in-house by Antengene's R&D team, ATG-022 is an antibody-drug-conjugate targeting th...

2022-12-09 08:30 3017

Antengene Appoints Amily Zhang as its Chief Medical Officer

SHANGHAI and HONG KONG, Dec. 8, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEH...

2022-12-08 08:30 3376

Antengene Appoints Amily Zhang as its Chief Medical Officer

Antengene Highlights Encouraging ATG-008 Efficacy Results From TORCH-2 Study in Combination with PD-1 Antibody in Relapsed/Metastatic Cervical Cancer

* An objective response rate (ORR) of 52.4% was observed in relapsed or metastatic cervical cance...

2022-11-15 16:51 2088

Antengene Presents Promising Results from Four Preclinical Studies at the 2022 Society for Immunotherapy of Cancer Annual Meeting

- Oral presentation highlights preclinical data with ATG-031, an in-house discovered anti-CD24 mo...

2022-11-11 08:30 2568

Preliminary Results from Two Clinical Studies of Selinexor to be Presented at 2022 ASH Annual Meeting

- Poster with updated Phase Ib TOUCH results suggest selinexor plus GemOx could provide a therapeut...

2022-11-07 14:38 1555

Antengene Announces IND Approval for the Phase I STAMINA-001 Study to Evaluate ATG-037 (CD73 Inhibitor) for the Treatment of Locally Advanced or Metastatic Solid Tumors in China

- ATG-037, an inhouse asset developed by Antengene and with global rights, has been approved t...

2022-11-02 20:07 2599

Antengene Receives U.S. FDA Clearance of IND Application for Phase I Trial of Small Molecule ERK1/2 Inhibitor ATG-017 in Patients with Advanced Solid Tumors

* ATG-017 is a small molecule ERK1/2 inhibitor and Antengene has obtained exclusive global rights...

2022-10-31 20:22 2728

Antengene to Host Research and Development Day on November 15th and 17th, 2022

* Virtual English Session: Tuesday, November 15 at 8:30 AM – 12:00 PM Eastern Time November 15 at ...

2022-10-27 11:07 3191

Antengene Announces XPOVIO® Regulatory Approval in Taiwan for the Treatment of Relapsed and/or Refractory Multiple Myeloma and Diffuse Large B-Cell Lymphoma

- XPOVIO® is the first and only exportin 1 (XPO1) inhibitor approved in Taiwan - Anten...

2022-10-21 20:37 4944

Antengene Announces Upcoming Presentations at the 2022 Society for Immunotherapy of Cancer Annual Meeting

* Oral presentation highlights preclinical data of ATG-031, an in-house discovered anti-CD24 mono...

2022-10-08 10:43 2170

Antengene Announces ATG-101 Granted Orphan Drug Designation by the U.S. FDA

SHANGHAI and BUCKS COUNTY, Pa., Sept. 20, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Ante...

2022-09-19 09:34 1820

Antengene Unveils Its First Australian Office to Continue Expanding Global Presence

SHANGHAI and HONG KONG, Sept. 14, 2022 /PRNewswire/ -- Antengene recently unveileda new office spac...

2022-09-14 08:30 3980

Antengene Unveils Its First Australian Office to Continue Expanding Global Presence

Antengene to Present at Upcoming Industry Conferences

SHANGHAI and HONG KONG, Sept. 9, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SE...

2022-09-09 14:43 1327

Antengene Announces XPOVIO® Included for Reimbursement by the PBS in Australia for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma

* XPOVIO® (selinexor) is the first and only selective inhibitor of nuclear export (SINE) inhibito...

2022-09-01 08:30 2905

Antengene Announces Interim 2022 Financial Results and Provides Corporate Update

- Revenue of RMB 53.96 million mainly driven by the commercial launch of XPOVIO® (selinexor) in Mai...

2022-08-31 08:29 2735

Antengene Announces First Patient Dosed of Small Molecule ATR ATG-018 for the Treatment of Patients with Advanced Solid Tumors and Hematologic Malignancies in Australia

* ATG-018, a global rights asset developed by Antengene's internal R&D team, is anorally-bioavail...

2022-08-16 08:30 2954

Antengene Announces First Patient Dosed in the PROBE-CN Study of ATG-101 (PD-L1/4-1BB Bispecific Antibody) for the Treatment of Solid Tumors and Non-Hodgkin Lymphoma

* ATG-101 is a novel PD-L1/4-1BB bispecific antibody. It is Antengene's first in-house developed ...

2022-08-03 08:30 2090